Health Innovation Fund

Obatala Sciences is a biotechnology company focused on addressing the economic challenges posed by obesity and diabetes, which collectively amount to a substantial financial burden. The company has developed a humanized adipose tissue model system that serves as an advanced in vitro platform for tissue engineering and drug discovery. This three-dimensional screening tool facilitates disease modeling, cell assays, and tissue analysis, thereby enabling academic and pharmaceutical researchers to identify effective drug compounds more efficiently. By emphasizing the role of body fat as a functional organ that regulates health and disease, Obatala Sciences aims to streamline the testing processes for potential treatments targeting obesity, diabetes, and related metabolic diseases.

Prolira BV is a Dutch company based in Utrecht that specializes in developing medical technology for the early detection of delirium, an acute brain failure condition. Founded in 2015, Prolira has introduced DeltaScan, an EEG-based device designed to monitor brain activity and facilitate timely treatment for patients at risk of acute encephalopathy and delirium. The DeltaScan system comprises a single-use electrode patch, known as the DeltaScan Patch, and the DeltaScan Monitor, which employs a validated proprietary algorithm to analyze EEG data. This innovative approach aims to enhance patient recovery by supporting clinicians in identifying and addressing delirium, a condition that affects approximately 20 million patients annually in hospitals across Europe and the United States, leading to significant cognitive impairment and increased healthcare costs.

FABPulous is a healthcare company based in The Netherlands, founded as a spin-off from Maastricht University in 2008. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created a novel handheld disposable plasma separation device that enables rapid preparation of plasma from a drop of blood, facilitating point-of-care and home testing. This device can be integrated with various in vitro diagnostic platforms, such as lateral flow devices. The primary product under development is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which aids in the first-line diagnosis of acute myocardial infarction. By providing a simple and efficient diagnostic tool, FABPulous aims to enhance the speed and accuracy of medical assessments in critical care settings.

Prolira BV is a Dutch company based in Utrecht that specializes in developing medical technology for the early detection of delirium, an acute brain failure condition. Founded in 2015, Prolira has introduced DeltaScan, an EEG-based device designed to monitor brain activity and facilitate timely treatment for patients at risk of acute encephalopathy and delirium. The DeltaScan system comprises a single-use electrode patch, known as the DeltaScan Patch, and the DeltaScan Monitor, which employs a validated proprietary algorithm to analyze EEG data. This innovative approach aims to enhance patient recovery by supporting clinicians in identifying and addressing delirium, a condition that affects approximately 20 million patients annually in hospitals across Europe and the United States, leading to significant cognitive impairment and increased healthcare costs.

NightBalance B.V. is a company established by alumni of TU Delft, originating from research conducted at the Delft University of Technology in 2007 focused on enhancing positional therapy aids. Founded in 2009, NightBalance specializes in the development of the Sleep Position Trainer, a smart therapeutic device designed to address sleep apnea. This innovative therapy monitors patients' sleep behavior and actively prevents positional obstructive sleep apnea, allowing individuals to achieve more comfortable and restful sleep.

FABPulous is a healthcare company based in The Netherlands, founded as a spin-off from Maastricht University in 2008. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created a novel handheld disposable plasma separation device that enables rapid preparation of plasma from a drop of blood, facilitating point-of-care and home testing. This device can be integrated with various in vitro diagnostic platforms, such as lateral flow devices. The primary product under development is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which aids in the first-line diagnosis of acute myocardial infarction. By providing a simple and efficient diagnostic tool, FABPulous aims to enhance the speed and accuracy of medical assessments in critical care settings.

DirectDerm operates a medical consulting platform designed to connect patients and healthcare providers with board-certified dermatologists for skin-related medical issues. The platform streamlines the process by allowing the transmission of patient history and images, facilitating quick communication between patients or referring medical providers and dermatologists. This enables patients to receive specialized care and advanced treatment options efficiently, ensuring timely consultations for various dermatological concerns.

FABPulous is a healthcare company based in The Netherlands, founded as a spin-off from Maastricht University in 2008. The company specializes in developing and marketing diagnostic solutions for primary care and emergency medicine. FABPulous has created a novel handheld disposable plasma separation device that enables rapid preparation of plasma from a drop of blood, facilitating point-of-care and home testing. This device can be integrated with various in vitro diagnostic platforms, such as lateral flow devices. The primary product under development is a rapid test for the cardiac biomarker heart-type fatty acid binding protein (H-FABP), which aids in the first-line diagnosis of acute myocardial infarction. By providing a simple and efficient diagnostic tool, FABPulous aims to enhance the speed and accuracy of medical assessments in critical care settings.